<unk>  is a monoclonal antibody that is FDA approved for the treatment of prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.   Common adverse reactions include fever and rash.
Palivizumab
Motavizumab
Ravulizumab
Natalizumab
Mogamulizumab
Tildrakizumab
Ixekizumab
Risankizumab